Please login to the form below
Sun Pharmaceutical
This page shows the latest Sun Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Sun Pharmaceutical’s Ilumya (tildrakizumab) in recent years.
Latest news
-
Teva among generic drugmakers hoping to settle US antitrust probe
As well as Teva, India-domiciled drugmaker Sun Pharmaceutical has also been in talks with the DoJ to settle the allegations.
-
Sun Pharma passes milestone with novel psoriasis drug approval
India’s largest drugmaker Sun Pharmaceutical has picked up its first FDA approval for a novel drug, getting the nod for plaque psoriasis therapy Ilumya. ... Ilumya isn’t entirely home-grown, as Sun Pharma licensed the interleukin-23 (IL-23) inhibitor
-
Merck and Sun Pharma part company on branded generics
Will continue partnership on diabetes and inflammatory disorder projects. Merck &Co and India's Sun Pharmaceutical Industries have agreed to dissolve a joint venture set up in 2011 to develop and ... Sun acquired global rights to tildrakizumab (MK-3222)
-
Daiichi Sankyo offloads stake in India's Sun Pharma
Daiichi Sankyo has found a buyer for its $3.6bn holding in India's Sun Pharmaceutical almost immediately after putting the stake up for sale. ... The merger of Sun and Ranbaxy created the world's fifth largest speciality generic pharmaceutical company
-
Ranbaxy hit with EU import ban on antibiotic
Ranbaxy is the subject of $4bn takeover bid from fellow Indian firm Sun Pharmaceutical that would offer its current majority shareholder Daiichi Sankyo a partial exit.
Teva among generic drugmakers hoping to settle US antitrust probe
Sun Pharma passes milestone with novel psoriasis drug approval
Merck and Sun Pharma part company on branded generics
Daiichi Sankyo offloads stake in India's Sun Pharma
Ranbaxy hit with EU import ban on antibiotic
More from news
Approximately 2 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
India's Sun Pharmaceutical has partnered with Mitsubishi Tanabe Pharma to distribute and market 14 prescription drugs in Japan that Sun recently acquired from Novartis. ... No financial terms were disclosed. Genentech signed an exclusive licence [global
-
Pharma deals during April 2014
April also saw Sun Pharmaceutical Industries relieving Daiichi Sankyo (63.9% owner) of the troubled Ranbaxy Laboratories to create India's largest pharma company, leading in 13 speciality segments, with estimated ... is rumoured that a solution will be
-
Deal Watch table for June 2013
Pfizer (Wyeth) Takeda / Teva Sun Pharmaceutical. Patent settlement. Infringement of Protonix patent. ... 39.5. BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)†. Collaboration and licence.
-
Pharma deals during June 2013
Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead ... damages (Teva $1.6bn and Sun Pharma $550m); Pfizer
Deal Watch September 2016
Pharma deals during April 2014
Deal Watch table for June 2013
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
-
Senior Account Manager
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- BMS’s oral AML therapy Onureg receives EU approval
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Breaking Down the Wall: Blockchain in Healthcare and Pharma
- Building Better Patient Advocates Through Authentic Partnerships
- Virgo Health makes two hires to leadership team
- Hanover Health appoints Aleksandra Lugović as an associate director
- GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy
- Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval
- Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- Diversity and inclusion in clinical trials
- BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Numbers, navigation, and narratives: digital storytelling in medical communications
- Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
- Is this common data mistake killing your digital patient recruitment?
- Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
- The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
- By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
